SRC and prostate carcinoma: During the last decade, CCL5 has been shown to be an inductor of resistance to taxane [77], CDDP [78], tamoxifen [79] and Src inhibitors [80] in models of prostate cancer, ovarian cancer and breast cancer, respectively.